170 related articles for article (PubMed ID: 11181324)
1. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
3. A case of bronchial carcinoid: diagnosis and follow-up with 111In-DTPA-octreotide.
Orsolon P; Bagni B; Basadonna P; Geatti O; Talmassons G; Guerra UP
Q J Nucl Med; 1995 Dec; 39(4):311-4. PubMed ID: 8624794
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy.
Bombardieri E; Crippa F; Cataldo I; Chiti A; Seregni E; Soresi E; Boffi R; Invernizzi G; Buraggi GL
Eur J Cancer; 1995; 31A(2):184-8. PubMed ID: 7718323
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
6. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
7. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
8. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
[TBL] [Abstract][Full Text] [Related]
10. The value of octreotide scintigraphy in patients with lung cancer.
Kwekkeboom DJ; Kho GS; Lamberts SW; Reubi JC; Laissue JA; Krenning EP
Eur J Nucl Med; 1994 Oct; 21(10):1106-13. PubMed ID: 7828621
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; de Herder WW; Reubi JC; Lamberts SW
Digestion; 1994; 55 Suppl 3():54-9. PubMed ID: 7698538
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
13. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors in meningiomas: a scintigraphic study using 111In-DTPA-D-Phe-1-octreotide.
Maini CL; Tofani A; Sciuto R; Carapella C; Cioffi R; Crecco M
Nucl Med Commun; 1993 Jul; 14(7):550-8. PubMed ID: 8355914
[TBL] [Abstract][Full Text] [Related]
15. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
16. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
[TBL] [Abstract][Full Text] [Related]
18. High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients.
Hildebrandt G; Scheidhauer K; Luyken C; Schicha H; Klug N; Dahms P; Krisch B
Acta Neurochir (Wien); 1994; 126(2-4):63-71. PubMed ID: 8042557
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.
Gibril F; Reynolds JC; Doppman JL; Chen CC; Venzon DJ; Termanini B; Weber HC; Stewart CA; Jensen RT
Ann Intern Med; 1996 Jul; 125(1):26-34. PubMed ID: 8644985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]